[1]谢金平,张雪瑞,张 赫,等.典型发达国家药品采购模式研究及启示[J].卫生经济研究,2022,39(1):64-68.
　XIE Jin-ping,ZHNAG Xue-rui,ZHANG He,et al.Study on Drug Purchasing Mode of Typical Developed Countries and its Enlightenment[J].Journal Press of Health Economics Research,2022,39(1):64-68.
点击复制

典型发达国家药品采购模式研究及启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年1期
页码:
64-68
栏目:
他山之石
出版日期:
2022-01-07

文章信息/Info

Title:
Study on Drug Purchasing Mode of Typical Developed Countries and its Enlightenment
作者:
谢金平1;  张雪瑞1;  张 赫1; 刘 越1;  邵 蓉1
1.中国药科大学药品监管科学研究院，江苏 南京211198
Author(s):
XIE Jin-ping;  ZHNAG Xue-rui;  ZHANG He;  LIU Yue;  SHAO Rong
Institute of regulatory science, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
通过对美国、英国、德国、荷兰四种药品采购模式的特点、产生的影响进行分析; 认为药品采购政策是各个国家特定国情下的产物; 国际上并没有统一的采购模式可以完全适用于某个国家。各国采购模式的共性之处：降低药品价格、节省医保基金支出是药品采购的核心出发点; 价格是主要但非唯一的考量因素; 综合性价比越来越受到重视。当过度关注价格时; 应考虑可能产生的供应问题; 以及品种遴选、频繁采购对患者用药的影响。
Keywords:
drug procurement model;  American collection organization group procurement;  British government procurement;  German statutory health insurance fund procurement;  Dutch health insurance company procurement
分类号:
R95
文献标志码:
A
摘要:
药品采购模式；美国集团采购组织采购；英国政府采购；德国法定医保基金采购；荷兰健康保险公司采购
Abstract:
Based on the analysis of the characteristics and effects of four drug procurement modes, it is considered that the drug procurement policy is the product of the specific national conditions of each country, and there is no unified international procurement model that can be fully applied to another country. The commonness of the procurement model of various countries: reducing drug prices and saving medical insurance fund expenditure is the core starting point of drug procurement, while price is the main but not the only consideration, and more and more attention has been paid to the comprehensive performance-to-price ratio. When paying too much attention to price, we should consider the possible supply problems, as well as the impact of variety selection and frequent procurement on patients' drug use.

参考文献/References:

[1] 张雅娟，方来英.药品集中采购制度的发展与改革研究[J].中国药房，2020，31（21）：2561-2566.
[2] 于长永.“4+7”药品带量采购的实践效果与制度隐忧[J].西南民族大学学报（人文社科版），2020，41（4）：34-39.
[3] 何江江，唐密，丛鹂萱，等.国家组织药品集中采购和使用试点对临床用药管理与使用的影响[J].中国卫生资源，2021，24（1）：29-31.
[4] 熊康，陈昊.我国非国家组织药品集中采购模式比较[J].中国卫生资源，2021，24（1）：20-23.
[5] HSCA.What Is a GPO?[EB/OL].[2020-8-11].https://www.supplychainassociation.org/about-us/what-is-gpo.
[6] Cornell Law School.42 CFR§1001.952-Exceptions[EB/OL].[2020-08-11].https://www.law.cornell.edu/cfr/text/42/1001.952.
[7] 丛鹂萱，陈珉惺，邹璇，等.美国集团采购组织核心要素介绍及与深圳模式对比分析[J].中国卫生经济，2019，38（12）：113-116.
[8] Burns L R,Briggs A D.Hospital purchasing alliances:Ten years after[J].Health care management review,2018,45(3):1.
[9] Curtis Rooney.Drug shortages:GPOs are part of the solution [EB/OL].[2013-12-01].https://www.jhconline.com/drug-shortages-gpos-are-part-of-the-solution.html.
[10] Roxanne Nelson.GPOs to Blame for Drug Shortages,Says Physicians Group [EB/OL].[2013-01-24].https://www.medscape.com/viewarticle/778146.
[11] Hu Qiaohai,Schwarz L B.Do GPOs Promote or Stifle Competition in Healthcare Pr-oduct Supply Chains?[J].RCHE Publications,2008.
[12] 李滔，王秀峰，赵坤.英国卫生体制对我国医改的启示[J].中国全科医学，2015，18（34）：4157-4161.
[13] 王小万，陈丽萍，刘丽杭.英国国民卫生服务制度（NHS）的结构性改革与治理模式[J].中国卫生政策研究，2017，10（11）：27-35.
[14] Specialist Pharmacy Service.An overview of NHS Procurement of Medicines and Pharmaceutical Products and Services for acute care in the United Kingdom updated Septemb-er 2018[EB/OL]. [2018-12-14].https://www.sps.nhs.uk/articles/an-overview-of-nhs-procurement-of-medicines-and-pharmaceutical-products-and-services-for-acute-care-in-the-united-kingdom.
[15] 国家发展改革委经济研究所课题组，王蕴，刘树杰，等.英国药品流通体制考察报告[J].中国物价，2013（7）：47-51.
[16] 房珊杉，孙纽云，梁铭会.德国医疗保障体系改革及启示[J].中国卫生政策研究，2013，6（1）：28-33.
[17] Ehlers A,Rybak C,Willh?觟ft C.Healthcare and reimbursement of medicines in Germany current problems,challenges and reform of the healthcare sector[EB/OL].[2010-11-01].https://content.next.westlaw.com/0-504-6248?__lrTS=20200825142428515&transitionType=Default&contextData=(sc.Default)&firstPage=true.
[18] Progenerika.Generika In Zahlen 2019-So Sichern Generika Die Arzneimittelversorgun-g[EB/OL].[2020-06-18].https://www.progenerika.de/publikationen/generika-in-zahlen-2.
[19] 孙东雅，范娟娟.荷兰医疗保险制度改革研究[J].中国医疗保险，2012（5）：66-68.
[20] Berenschot.Effects of the preference policy for pharmaceuticals on the availability of medicines[EB/OL].[2018-01-11].https://www.berenschot.nl/publish/pages/6054/effects_preference_policy-berenschot.pdf.
[21] Arickx F,Bormans V,Leveque F,et al.Pharmaceutical policy in the Netherlands:fro-m price regulation toward managed competition in 'Pharmaceutical Markets and Insurance Worldwide'[J].Health Economics Health Services Res,2010,8(22):53-76.
[22] Pastoors,I.The preference policy:implications for patients[R]. Wageningen University and Research Centre (WUR),2011.
[23] 李大平.药价虚高的成因分析与治理对策——质疑医药分开[J].卫生经济研究，2011（4）：7-9.

更新日期/Last Update: 2022-01-07